Top-News

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
345,80 €
-0,4 €
-0,12%
04.12.25
Depot/Watchlist
Marktkapitalisierung *
34,95 Mrd. €
Streubesitz
16,26%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
3,00%
Index-Zuordnung
-

Roche Holding News

06.05.25 - GlobeNewswire
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 ...
30.04.25 - GlobeNewswire
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
Positive recommendation based on clinical, real-​world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example ...
29.04.25 - GlobeNewswire
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment.  The device ...
25.04.25 - GlobeNewswire
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household ...
24.04.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter
Group sales grew by 6% 1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. Pharmaceuticals Division sales ...
24.04.25 - GlobeNewswire
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachs­tums­kurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort
Konzernverkäufe stiegen um 6% 1 zu konstanten Wechselkursen (CER; 7% in CHF) dank hoher Nachfrage nach innovativen Medikamenten und diagnostischen Lösungen. ...
23.04.25 - GlobeNewswire
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device 1 set to transform cardiac care This ...
22.04.25 - GlobeNewswire
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
USD 50 billion commitment includes new state-​of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, ...
14.04.25 - GlobeNewswire
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus ...
03.04.25 - GlobeNewswire
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
New trontinemab data continue to support rapid and deep, dose-​dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys® pTau181 ...
03.04.25 - RiskmasterPro
Roche AG unter Druck: Warum die Deutsche Bank zum Verkauf der Aktie rät
Neueste Nachrichten von RiskMasterPro (Auszug) Im Spannungsfeld zwischen hoffnungsvollen Forschungsergebnissen und ernüchternden Analysteneinheiten steht Roche AG ...
02.04.25 - GlobeNewswire
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing ...
26.03.25 - RiskmasterPro
Roche in der Krise? Analysten warnen vor Risiken im Onkologiesektor
Die Aktienbewertung von Roche, einer der führenden Unternehmen im Bereich der Onkologie, hat einen markanten Kurswechsel hingelegt. Die US-Bank JPMorgan Chase & Co. ...
25.03.25 - GlobeNewswire
Roche Annual General Meeting 2025
Shareholders approved all proposals of the Board of Directors Severin Schwan was re-​elected as Chairman of the Board of Directors; all other Board members standing for ...
25.03.25 - GlobeNewswire
Roche Generalversammlung 2025
Alle Anträge des Verwaltungsrates genehmigt Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Mitgliedern des ...
17.03.25 - GlobeNewswire
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy ...
12.03.25 - GlobeNewswire
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
Agreement allows for a range of potentially best-​in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will ...
07.03.25 - GlobeNewswire
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to ...
05.03.25 - GlobeNewswire
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit 1 The filing application is based on ...
02.03.25 - GlobeNewswire
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
First-​ever head-​to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-​breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-...

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »